Kai Zhu1, Ying Li2, Yikai Xu3. 1. Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: zhukai860804@smu.edu.cn. 2. Department of Paediatrics, Heping Hospital affiliated to Changzhi Medical College, Changzhi 046000, China. Electronic address: liying6666888888@sina.com. 3. Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: Yikai@smu.edu.cn.
Abstract
AIMS: N6-Methyladenosine (m6A) is the most frequent posttranscriptional modification and plays important roles in tumorigenesis and metastasis. The roles of fat mass and obesity-associated (FTO) in metabolic diseases have been widely explored. However, the molecular mechanisms and physiological functions of FTO in prostate cancer remain largely unknown. This study aimed to explore the exact functions of FTO in the progression of prostate cancer metastasis. MAIN METHODS: Dot blot and m6A RNA methylation quantification assays were performed to determine m6A levels. The protein and mRNA expression levels were detected using immunoblot (IB) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analyses. Cell invasion and migration abilities were measured using transwell and wound healing assays. Bioinformatics was used to measure the expression level of FTO and possible correlation between FTO levels and advanced tumor stage. Immunofluorescence (IF) was performed to measure the cellular localization of FTO. KEY FINDINGS: FTO was downregulated in prostate cancer tissues and cell lines, and the m6A content was increased. Importantly, patients with lower FTO expression had advanced tumor stage and higher Gleason scores. Gain- and loss-of-function assays revealed that FTO inhibits prostate cancer cell invasion and migration in vitro. Moreover, we confirmed that FTO can decrease the total m6A level. SIGNIFICANCE: The present study revealed that the FTO m6A demethylase inhibits prostate cancer cell invasion and migration by regulating total m6A levels.
AIMS: N6-Methyladenosine (m6A) is the most frequent posttranscriptional modification and plays important roles in tumorigenesis and metastasis. The roles of fat mass and obesity-associated (FTO) in metabolic diseases have been widely explored. However, the molecular mechanisms and physiological functions of FTO in prostate cancer remain largely unknown. This study aimed to explore the exact functions of FTO in the progression of prostate cancer metastasis. MAIN METHODS: Dot blot and m6A RNA methylation quantification assays were performed to determine m6A levels. The protein and mRNA expression levels were detected using immunoblot (IB) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analyses. Cell invasion and migration abilities were measured using transwell and wound healing assays. Bioinformatics was used to measure the expression level of FTO and possible correlation between FTO levels and advanced tumor stage. Immunofluorescence (IF) was performed to measure the cellular localization of FTO. KEY FINDINGS:FTO was downregulated in prostate cancer tissues and cell lines, and the m6A content was increased. Importantly, patients with lower FTO expression had advanced tumor stage and higher Gleason scores. Gain- and loss-of-function assays revealed that FTO inhibits prostate cancer cell invasion and migration in vitro. Moreover, we confirmed that FTO can decrease the total m6A level. SIGNIFICANCE: The present study revealed that the FTO m6A demethylase inhibits prostate cancer cell invasion and migration by regulating total m6A levels.
Authors: José Manuel Sánchez-Maldonado; Ricardo Collado; Antonio José Cabrera-Serrano; Rob Ter Horst; Fernando Gálvez-Montosa; Inmaculada Robles-Fernández; Verónica Arenas-Rodríguez; Blanca Cano-Gutiérrez; Olivier Bakker; María Inmaculada Bravo-Fernández; Francisco José García-Verdejo; José Antonio López López; Jesús Olivares-Ruiz; Miguel Ángel López-Nevot; Laura Fernández-Puerta; José Manuel Cózar-Olmo; Yang Li; Mihai G Netea; Manuel Jurado; Jose Antonio Lorente; Pedro Sánchez-Rovira; María Jesús Álvarez-Cubero; Juan Sainz Journal: Cancers (Basel) Date: 2022-05-12 Impact factor: 6.575
Authors: Xiaolin Qu; Yongqiu Zhang; Xianzheng Sang; Ding Ren; Hong Zhao; Stephen T C Wong Journal: Cancers (Basel) Date: 2022-06-29 Impact factor: 6.575